EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 212 / Numéro 3-4 (2018) Biologie Aujourd'hui, 212 3-4 (2018) 69-76 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 212, Numéro 3-4, 2018
Page(s) 69 - 76
DOI https://doi.org/10.1051/jbio/2019002
Publié en ligne 11 avril 2019
  • Antonarakis, E.S., Small, E.J., Petrylak, D.P., Quinn, D.I., Kibel, A.S., Chang, N.N., Dearstyne, E., Harmon, M., Campogan, D., Haynes, H., Vu T., Sheikh N.A., Drake C.G. (2018). Antigen-Specific CD8 lytic phenotype induced by Sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival. Clin Cancer Res , 24, 4662–4671. [CrossRef] [PubMed] [Google Scholar]
  • Arbyn, M., Xu, L., Simoens, C., Martin-Hirsch, P.P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev , 5, CD009069. [PubMed] [Google Scholar]
  • Badoual, C., Hans, S., Merillon, N., Van Ryswick, C., Ravel, P., Benhamouda, N., Levionnois, E., Nizard, M., Si-Mohamed, A., Besnier, N., Gey A., Rotem-Yehudar R., Péré H., Tran T., Guérin C.L., Chauvat A., Dransart E., Alanio C., Albert S., Barry B., Sandoval F., Quintin-Colonna F., Bruneval P., Fridman W.H., Lemoine F.M, Oudard S., Johannes L., Olive D., Brasnu D., Tartour E. (2013). PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res , 73, 128–138. [Google Scholar]
  • Bassani-Sternberg, M., Braunlein, E., Klar, R., Engleitner, T., Sinitcyn, P., Audehm, S., Straub, M., Weber, J., Slotta-Huspenina, J., Specht, K., Martignoni M.E., Werner A., Hein R.H., Busch D., Peschel C., Rad R., Cox J., Mann M., Krackhardt A.M. (2016). Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun, 7, 13404. [CrossRef] [PubMed] [Google Scholar]
  • Blanc, C., Granier, C., Tartour, E. (2017). Vaccination antitumorale. Innovations Ther Oncol , 3, 149–157. [Google Scholar]
  • Busek, P., Mateu, R., Zubal, M., Kotackova, L., Sedo, A. (2018). Targeting fibroblast activation protein in cancer − Prospects and caveats. Front Biosci (Landmark Ed) , 23, 1933–1968. [Google Scholar]
  • Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., Linette G.P. (2015). Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science , 348, 803–808. [Google Scholar]
  • Corbière, V., Chapiro, J., Stroobant, V., Ma, W., Lurquin, C., Lethe, B., van Baren, N., Van den Eynde, B.J., Boon, T., Coulie, P.G. (2011). Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res, 71, 1253-1262. [Google Scholar]
  • Draghiciu, O., Nijman, H.W., Hoogeboom, B.N., Meijerhof, T., Daemen, T. (2015). Sunitinib depletes myeloid-derived suppressor cells and synergizes with a cancer vaccine to enhance antigen-specific immune responses and tumor eradication. Oncoimmunology , 4, e989764. [CrossRef] [PubMed] [Google Scholar]
  • Enamorado, M., Iborra, S., Priego, E., Cueto, F.J., Quintana, J.A., Martinez-Cano, S., Mejias-Perez, E., Esteban, M., Melero, I., Hidalgo, A., Sancho D. (2017). Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8(+) T cells. Nat Commun , 8, 16073. [CrossRef] [PubMed] [Google Scholar]
  • Figlin, R.A. (2014). A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma. Immunotherapy , 6, 261–268. [CrossRef] [PubMed] [Google Scholar]
  • Galvez-Cancino, F., Lopez, E., Menares, E., Diaz, X., Flores, C., Caceres, P., Hidalgo, S., Chovar, O., Alcantara-Hernandez, M., Borgna, V., Varas-Godoy M., Salazar-Onfray F., Idoyaga J., Lladser A. (2018). Vaccination-induced skin-resident memory CD8(+) T cells mediate strong protection against cutaneous melanoma. Oncoimmunology , 7, e1442163. [CrossRef] [PubMed] [Google Scholar]
  • Gatti-Mays, M.E., Redman, J.M., Collins, J.M., Bilusic, M. (2017). Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother , 13, 2561–2574. [Google Scholar]
  • Granier, C., De Guillebon, E., Blanc, C., Roussel, H., Badoual, C., Colin, E., Saldmann, A., Gey, A., Oudard, S., Tartour, E. (2017). Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO open, 2, e000213. [CrossRef] [PubMed] [Google Scholar]
  • Guo, Y., Lei, K., Tang, L. (2018). Neoantigen vaccine delivery for personalized anticancer immunotherapy. Front Immunol , 9, 1499. [CrossRef] [PubMed] [Google Scholar]
  • Hale, D., Mittendorf, E., Brown, T., Clifton, G., Vreeland, T.J., Myers, J., Peace, K., Jackson, D., Greene, J., Holmes, J.P., Peoples, G.E. (2018). Pre-specified interim analysis of a randomized phase 2b trial of trastuzumab + nelipeptimut-S (NeuVax) vs trastuzumab for the prevention of recurrence. Ann Oncol, 29, vii400–viii441. [CrossRef] [Google Scholar]
  • Kantoff, P.W., Higano, C.S., Shore, N.D., Berger, E.R., Small, E.J., Penson, D.F., Redfern, C.H., Ferrari, A.C., Dreicer, R., Sims, R.B., Xu Y., Frohlich M.W., Schellhammer P.F.; IMPACT Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411–422. [CrossRef] [PubMed] [Google Scholar]
  • Kenter, G.G., Welters, M.J., Valentijn, A.R., Lowik, M.J., Berends-van der Meer, D.M., Vloon, A.P., Essahsah, F., Fathers, L.M., Offringa, R., Drijfhout, J.W., Wafelman A.R., Oostendorp J., Fleuren G.J., van der Burg S.H., Melief C.J. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med , 361, 1838-1847. [CrossRef] [PubMed] [Google Scholar]
  • Klebanoff, C.A., Wolchok, J.D. (2018). Shared cancer neoantigens: making private matters public. J Exp Med , 215, 5–7. [CrossRef] [PubMed] [Google Scholar]
  • Klein, O., Davis, I.D., McArthur, G.A., Chen, L., Haydon, A., Parente, P., Dimopoulos, N., Jackson, H., Xiao, K., Maraskovsky, E., Hopkins W., Stan R., Chen W., Cebon J. (2015). Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX vaccine in patients with advanced melanoma. Cancer Immunol Immunother , 64, 507–518. [CrossRef] [PubMed] [Google Scholar]
  • Laumont, C.M., Vincent, K., Hesnard, L., Audemard, E., Bonneil, E., Laverdure, J.P., Gendron, P., Courcelles, M., Hardy, M.P., Côté, C., Durette C., St-Pierre C., Benhammadi M., Lanoix J., Vobecky S., Haddad E., Lemieux S., Thibault P., Perreault C. (2018). Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med , 10, pii: eaau 5516. [Google Scholar]
  • Liu, D.Q., Lu, S., Zhang, L.X., Ji, M., Liu, S.Y., Wang, S.W., Liu, R.T. (2018). An indoleamine 2, 3-dioxygenase siRNA nanoparticle-coated and Trp2-displayed recombinant yeast vaccine inhibits melanoma tumor growth in mice. J Control Release , 273, 1–12. [CrossRef] [PubMed] [Google Scholar]
  • Lowenfeld, L., Mick, R., Datta, J., Xu, S., Fitzpatrick, E., Fisher, C.S., Fox, K.R., DeMichele, A., Zhang, P.J., Weinstein, S.P., Roses R.E., Czerniecki B.J. (2017). Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: results of randomized selection design trial. Clin Cancer Res , 23, 2961–2971. [CrossRef] [PubMed] [Google Scholar]
  • Mami-Chouaib, F., Blanc, C., Corgnac, S., Hans, S., Malenica, I., Granier, C., Tihy, I., Tartour, E. (2018). Resident memory T cells, critical components in tumor immunology. J Immunother Cancer , 6, 87. [CrossRef] [Google Scholar]
  • Marty, R., Kaabinejadian, S., Rossell, D., Slifker, M.J., van de Haar, J., Engin, H.B., de Prisco, N., Ideker, T., Hildebrand, W.H., Font-Burgada, J., Carter, H. (2017). MHC-I genotype restricts the oncogenic mutational landscape. Cell, 171, 1272–1283 e1215. [CrossRef] [PubMed] [Google Scholar]
  • Massarelli, E., William, W., Johnson, F., Kies, M., Ferrarotto, R., Guo, M., Feng, L., Lee, J.J., Tran, H., Kim, Y.U., Haymaker C., Bernatchez C., Curran M., Zecchini Barrese T., Rodriguez Canales J., Wistuba I., Li L., Wang J., van der Burg S.H., Melief C.J., Glisson B. (2018). Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 Clinical Trial. JAMA Oncol, doi: 10.1001/jamaoncol.2018.4051. [Google Scholar]
  • McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., Watkins T.B., Shafi S., Murugaesu N., Mitter R., Akarca A.U., Linares J., Marafioti T., Henry J.Y., Van Allen E.M., Miao D., Schilling B., Schadendorf D., Garraway L.A., Makarov V., Rizvi N.A., Snyder A., Hellmann M.D., Merghoub T., Wolchok J.D., Shukla S.A., Wu C.J., Peggs K.S., Chan T.A., Hadrup S.R., Quezada S.A., Swanton C. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science , 351, 1463–1469. [CrossRef] [PubMed] [Google Scholar]
  • Mondini, M., Nizard, M., Tran, T., Mauge, L., Loi, M., Clemenson, C., Dugue, D., Maroun, P., Louvet, E., Adam, J., Badoual C., Johannes L., Vozenin M.C., Perfettini J.L., Tartour E., Deutsch E. (2015). Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck cancer. Mol Cancer Ther , 14, 1336–1345. [CrossRef] [Google Scholar]
  • Moreno, A.C.R., Porchia, B., Pagni, R.L., Souza, P.D.C., Pegoraro, R., Rodrigues, K.B., Barros, T.B., Aps, L., de Araujo, E.F., Calich, V.L.G., Ferreira, L.C.S. (2018). The combined use of melatonin and an indoleamine 2,3-dioxygenase-1 inhibitor enhances vaccine-induced protective cellular immunity to HPV16-associated tumors. Front Immunol , 9, 1914. [CrossRef] [PubMed] [Google Scholar]
  • Morera, Y., Sanchez, J., Bequet-Romero, M., Selman-Housein, K.H., de la Torre, A., Hernandez-Bernal, F., Martin, Y., Garabito, A., Pinero, J., Bermudez, C., de la Torre J., Ayala M., Gavilondo J.V. (2017). Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine, 35, 3582-3590. [CrossRef] [PubMed] [Google Scholar]
  • Nizard, M., Roussel, H., Diniz, M.O., Karaki, S., Tran, T., Voron, T., Dransart, E., Sandoval, F., Riquet, M., Rance, B., Marcheteau E., Fabre E., Mandavit M., Terme M., Blanc C., Escudie J.B., Gibault L., Barthes F.L.P., Granier C., Ferreira L.C.S., Badoual C., Johannes L., Tartour E. (2017). Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun , 8, 15221. [Google Scholar]
  • Nizard, M., Roussel, H., Tartour, E. (2016). Resident memory T cells as surrogate markers of the efficacy of cancer vaccines. Clin Cancer Res , 22, 530–532. [CrossRef] [PubMed] [Google Scholar]
  • Onodi, F., Maherzi-Mechalikh, C., Mougel, A., Ben Hamouda, N., Taboas, C., Gueugnon, F., Tran, T., Nozach, H., Marcon, E., Gey, A., Terme M., Bouzidi A., Maillere B., Kerzerho J., Tartour E., Tanchot C. (2018). High therapeutic efficacy of a new survivin LSP-cancer vaccine containing CD4(+) and CD8(+) T-cell epitopes. Front Oncol, 8, 517. [CrossRef] [PubMed] [Google Scholar]
  • Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., Chen C., Olive O., Carter T.A., Li S., Lieb D.J., Eisenhaure T., Gjini E., Stevens J., Lane W.J., Javeri I., Nellaiappan K., Salazar A.M., Daley H., Seaman M., Buchbinder E.I., Yoon C.H., Harden M., Lennon N., Gabriel S., Rodig S.J., Barouch D.H., Aster J.C., Getz G., Wucherpfennig K., Neuberg D., Ritz J., Lander E.S., Fritsch E.F., Hacohen N., Wu C.J. (2017). An immunogenic personal neoantigen vaccine for patients with melanoma. Nature , 547, 217–221. [CrossRef] [PubMed] [Google Scholar]
  • Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., Omokoko T., Vormehr M., Albrecht C., Paruzynski A., Kuhn A.N., Buck J., Heesch S., Schreeb K.H., Müller F., Ortseifer I., Vogler I., Godehardt E., Attig S., Rae R., Breitkreuz A., Tolliver C., Suchan M., Martic G., Hohberger A., Sorn P., Diekmann J., Ciesla J., Waksmann O., Brück A.K., Witt M., Zillgen M., Rothermel A., Kasemann B., Langer D., Bolte S., Diken M., Kreiter S, Nemecek R., Gebhardt C., Grabbe S., Höller C., Utikal J., Huber C., Loquai C., Türeci Ö. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature , 547, 222–226. [CrossRef] [PubMed] [Google Scholar]
  • Stanley, M. (2017). Tumour virus vaccines: hepatitis B virus and human papillomavirus. Philos Trans R Soc Lond B Biol Sci, 372 (1732), pii: 20160268 [CrossRef] [PubMed] [Google Scholar]
  • Sun, Y.Y., Peng, S., Han, L., Qiu, J., Song, L., Tsai, Y., Yang, B., Roden, R.B., Trimble, C.L., Hung, C.F., Wu, T.C. (2016). Local HPV recombinant vaccinia boost following priming with an HPV DNA vaccine enhances local HPV-specific CD8+ T-cell-mediated Tumor control in the genital tract. Clin Cancer Res, 22, 657–669. [CrossRef] [PubMed] [Google Scholar]
  • Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S., McPherson, J.M., Berzofsky, J.A. (2010). Blockade of TGF-beta enhances tumor vaccine efficacy mediated by CD8(+) T cells. Int J Cancer, 126, 1666–1674. [PubMed] [Google Scholar]
  • Tanyi, J.L., Bobisse, S., Ophir, E., Tuyaerts, S., Roberti, A., Genolet, R., Baumgartner, P., Stevenson, B.J., Iseli, C., Dangaj, D., Czerniecki B., Semilietof A., Racle J., Michel A., Xenarios I., Chiang C., Monos D.S., Torigian D.A., Nisenbaum H.L., Michielin O., June C.H., Levine B.L., Powell D.J. Jr, Gfeller D., Mick R., Dafni U., Zoete V., Harari A., Coukos G., Kandalaft L.E. (2018). Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med, 10 (436), pii: eaao5931. [CrossRef] [PubMed] [Google Scholar]
  • Terabe, M., Ambrosino, E., Takaku, S., O’Konek, J.J., Venzon, D., Lonning, S., McPherson, J.M., Berzofsky, J.A. (2009). Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res , 15, 6560–6569. [Google Scholar]
  • Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., Tartour, E. (2018). Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol, doi: 10.1007/s00281-018-0691-z. [Google Scholar]
  • Trimble, C.L., Morrow, M.P., Kraynyak, K.A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R.L., Denny, L., Giffear, M., Brown A.S., Marcozzi-Pierce K., Shah D., Slager A.M., Sylvester A.J., Khan A., Broderick K.E., Juba R.J., Herring T.A., Boyer J., Lee J., Sardesai N.Y., Weiner D.B., Bagarazzi M.L. (2015). Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet , 386, 2078–2088. [CrossRef] [PubMed] [Google Scholar]
  • Welters, M.J., van der Sluis, T.C., van Meir, H., Loof, N.M., van Ham, V.J., van Duikeren, S., Santegoets, S.J., Arens, R., de Kam, M.L., Cohen, A.F., van Poelgeest M.I., Kenter G.G., Kroep J.R., Burggraaf J., Melief C.J., van der Burg S.H. (2016). Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci Transl Med, 8, 334ra352. [CrossRef] [Google Scholar]
  • Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T.K., Fritsche, J., Weinschenk, T., Modrusan, Z., Mellman, I., Lill, J.R., Delamarre, L. (2014). Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature , 515, 572–576. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.